Refining Treatment Targets for the Management of PsoriasisPremiere Date: Friday, May 28, 2021
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, May 28, 2022
Note: Credit Is No Longer Available
|April W. Armstrong, MD, MPH
Associate Dean, Clinical Research
Professor of Dermatology
Director, Clinical Research Support, Southern California CTSI
Keck School of Medicine
University of Southern California
Los Angeles, CA
|Melinda Gooderham, MSc, MD, FRCPC
Medical Director, SKiN Centre for Dermatology
Assistant Professor, Department of Medicine
Peterborough Regional Health Centre
The interleukin (IL)-12 and IL-23/axis is complex and not fully understood but is currently considered to be the main pathogenic pathway of psoriasis (PsO). Understanding the pathogenesis of PsO offers key insights into efficacy and safety profiles for emerging agents. Monoclonal antibodies (mAbs) target the IL-12/23 axis, but the need for parenteral administration, risk of immunogenicity, potential adverse events, and loss of efficacy merits continued discovery and clinical trials.
In this CME Outfitters Snack, expert faculty evaluate the role of TYK2 versus JAK1, JAK2, and JAK3 signaling pathways in PsO as the differences in mechanisms of action offer new and effective options for patients with PsO.
At the end of this CE activity, participants should be able to:
- Evaluate the role of TYK2 versus JAK1, JAK2, and JAK3 signaling pathways in psoriasis (PsO) and their role as emerging treatment targets.
Supported through an educational grant from Bristol Myers Squibb
Dermatologists, nurse practitioners, pharmacists, and rheumatologists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.25 contact hour (0.025 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Note to PAs: PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Armstrong reports that she receives grants/research support from AbbVie Inc.; Boehringer Ingelheim/Parexel; Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; Janssen-Ortho, Inc; Janssen Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Leo Pharma Inc.; Modernizing Medicine; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharma; and UCB Pharma. She is on the speakers bureau for AbbVie Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme.
Dr. Gooderham reports that she receives research support from AbbVie Inc.; Akros Pharma Inc.; Amgen Inc.; Arcutis Biotherapeutics; Bausch Health; Boehringer Ingelheim; Bristol Myers Squibb Company; Celgene Corporation; Coherus BioSciences; Dermira, Inc.; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma; GlaxoSmithKline; Glenmark; Janssen Inc.; Kyowa Kirin Co., Ltd.; LEO Pharma Inc.; MedImmune; Merck & Co., Inc; Novartis; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Sun Pharmaceutical Industries Ltd.;Takeda Pharmaceutical Company Limited; and UCB Canada Inc. She is on the speakers bureau for AbbVie Inc.; Actelion; Amgen Inc.; Bausch Health; Boehringer Ingelheim; Celgene Corporation; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma; Glenmark; Janssen Inc.; LEO Pharma Inc.; Novartis; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Ltd.; and UCB Canada Inc. She is a consultant for AbbVie Inc.; Akros Pharma Inc.; Amgen Inc.; Arena Pharmaceuticals, Inc.; Bausch Health; Boehringer Ingelheim; Celgene Corporation; Eli Lilly and Company; Janssen Inc.; Kyowa Kirin Co., Ltd.; Sanofi; Sun Pharmaceutical Industries Ltd.; and UCB Canada Inc.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).